SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001636050-22-000031
Filing Date
2022-04-27
Accepted
2022-04-27 16:35:54
Documents
14
Period of Report
2022-04-27
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K siox-20220427.htm   iXBRL 8-K 51558
2 EX-99.1 siox8-k04272022exx991.htm EX-99.1 10624
6 GRAPHIC sioxa.jpg GRAPHIC 14099
  Complete submission text file 0001636050-22-000031.txt   233982

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT siox-20220427.xsd EX-101.SCH 1897
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT siox-20220427_lab.xml EX-101.LAB 26039
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT siox-20220427_pre.xml EX-101.PRE 13548
8 EXTRACTED XBRL INSTANCE DOCUMENT siox-20220427_htm.xml XML 12298
Mailing Address 130 WEST 42ND STREET 26TH FLOOR NEW YORK NY 10036
Business Address 130 WEST 42ND STREET 26TH FLOOR NEW YORK NY 10036 877-746-4891
Sio Gene Therapies Inc. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 853863315 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 22860311
SIC: 2834 Pharmaceutical Preparations